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Introduction 
Nucleoside and nucleotide analogues are of fundamental importance for all organisms. 
Therefore, nucleoside analogues are interesting target for drug discovery and development, 
mainly as potential antiviral and antitumor agents. A crucial disadvantage of natural 
nucleosides analogues is cleavage of the N-glycosidic bond by phosphorylases. Modification 
which increases resistance against enzymatic degradation is substitution of the sugar moiety 
furanose ring by a hydrocarbon ring. Many of such modified analogues – carbocyclic 
nucleosides1 – exhibit interesting antiviral activity. Several analogues containing 
conformationally locked bicyclic systems were also synthesized. Well known are carbocylic 
nucleosides with a fused cyclopropane moiety2 (bicyclo[3.1.0]hexane). Recently, novel 
conformationally locked carbocyclic nucleosides based on 2-oxabicyclo[2.2.1]heptane ring 
system were described3 (as precursors for carbocyclic locked nucleic acids). This thesis 
concerns the synthesis of biologically active compounds related to the carbocyclic nucleoside 
analogues. First part of the work is devoted to the synthesis of the conformationally locked 
carbocyclic nucleosides derived from bicyclo[2.2.1]heptane. These compounds were 
primarily designed for general biological activity screening. In the course of this work, 
compounds produced in our laboratory showed interesting antiviral properties against 
coxsackievirus B3 (Picornaviridae). These very promising findings of the preliminary 
biological tests led us to start the program targeted on development of novel coxsackievirus 
B3 inhibitors.       
 
Carbocyclic conformationally locked nucleosides  
First part of this chapter attends to a synthesis of novel racemic conformationally locked 
nucleoside analogues with bicyclo[2.2.1]hept-2-ene or -heptane ring substituted with 
nucleobase at the position 7 of the bicyclic scaffold (two series, syn and anti isomers). These 
bicyclic compounds could be considered as the conformationally locked carbapentofuranose 
nucleoside analogues. 
The synthetic strategy was based on construction of the nucleobases at the amino group of an 
appropriate aminobicycloalkene. The key intermediate in the synthesis of the syn-nucleosides 
was syn-amine 170 which was prepared in three simple steps from the commercially available 
bicyclo[2.2.1]hept-5-ene-2,2-dimethanol (98) (Scheme 1). The dibenzoyl derivative 109 was 
treated with ethyl azidoformate and intermediate triazoline derivatives 167x and 167y were 
cleaved without isolation with silica gel (Wagner-Meerwein rearrangement). This reaction 
afforded a mixture of carbamates 168 and 169 (2:3) which were easily separated by 
chromatography on a silica gel column. Free amine 170 was obtained in a good yield by 
deprotection with potassium hydroxide. Thymine nucleoside 171 was prepared in a moderate 
yield by reaction of  amine 170 with carbamate 95 in 1,4-dioxane at 100 °C and following 
pyrimidine ring closure catalyzed with Dowex 50. Saturated nucleoside 171 was obtained by 
hydrogenation using palladium(II) hydroxide as a catalyst. 
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Scheme 1. a) BzCl, pyridine, r.t., 91%; b) ethyl azidoformate, toluene, 6 h, 80 °C; c) silicagel, CH2Cl2, 2 h, 33% 
for 168, 47% for 169; d) KOH, EtOH-H2O, reflux, 14 h, 83%; e) 1. 1,4-dioxane, 100 °C, 3 h, 2. Dowex 50 (H+ 
cycle), 1,4-dioxane, 100 °C, 2.5 h, 50%; f) H2, Pd(OH)2/C, MeOH-H2O, 3 d, 71%. 
 
Amine 170 was also treated with 4,6-dichloropyrimidine-5-amine in ethanol in the presence of 
triethylamine (Scheme 2) and the purine ring was subsequently closed with triethyl 
orthoformate in the presence of concentrated hydrochloric acid to give 6-chloropurine 
derivative 174. Finally, position 6 of the purine ring was derivatized by ammonolysis (175) 
and nucleophilic substitution of the chlorine atom with cyclopropylamino group (176). Both 
unsaturated nucleosides were hydrogenated to give saturated nucleosides 177 and 178.  
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Scheme 2. a) 4,6-dichlorpyrimidine-5-amine, Et3N, EtOH, 100 °C, 6 d, 97%; b) 1. HC(OEt)3, HCl, 3 d 2. HCl, 
THF-H2O, 4 h, 79%; c) NH3 (l), 75 °C, 2 d, 95%; d) cyclopropylamine, MeOH, r.t., overnight, 92%; e) H2, 
Pd(OH)2/C , MeOH-H2O, 87% for 177, 85% for 178. 
 
Amine 170 was coupled with 4,6-dichloropyrimidine-2,5-diamine in the presence of 
triethylamine in ethanol, the obtained intermediate was treated with triethyl orthoformate and 
concentrated hydrochloric acid to give 2-amino-6-chloropurine nucleoside 179 (Scheme 3). 
The nucleoside analogue 179 was converted to guanine compound 180 by treatment with 
trifluoroacetic acid. The reaction of 179 with cyclopropylamine in methanol afforded 
compound 181. Saturated derivatives 182 and 183 were prepared by hydrogenation. 
 
 
Scheme 3. a) 1. 4,6-dichlorpyrimidine-2,5-diamine, Et3N, EtOH, 100 °C, 6 d, 2. HC(OEt)3, HCl, 4 d, 3. HCl, 
THF-H2O, 4 h, 79%; b) CF3COOH, H2O, 3 d, 94%; c) cyclopropylamine, MeOH, overnight, 94%; d) H2, 
Pd(OH)2/C, DMF, 87% for 182, MeOH-H2O, 80% for 183. 
 
Synthesis of other syn-nucleosides (without any substitution or bearing only one hydroxymethyl or 
hydroxy group) was realized in similar way as described above.  
Also, the synthesis of the anti-nucleosides was based on the construction of  nucleobases 
at the amino group (Scheme 4). Anti-amine 212 was prepared in six steps, starting 
from commercially available 1,2,3,4-tetrachloro-5,5-dimethoxycyclopentadiene 206. The 
chlorocyclopentadiene 206 was treated with acrolein, and the Diels-Alder intermediate - 
formyl derivative - was reacted with formaldehyde under basic conditions (NaOH) to yield 
the dihydroxymethyl derivative 207. Chlorine atoms were removed with sodium in liquid 
ammonia, and the free hydroxy groups were immediately protected by benzoylation. Ketone 
209 was then prepared by deketalization (Dowex 50, H+ cycle) in refluxing dioxane-water 
mixture. Reduction of the keto group was achieved by reaction with sodium borohydride in 
mixture of tetrahydrofuran and water. Due to the steric hindrance (hydroxymethyl group 
against double bond) only one isomer (anti) was obtained in very good yield. Finally, 
protected amino group was introduced by Ritter reaction with retention of the configuration. 
The free amine 212 was finally released by basic deprotection (KOH).  
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Scheme 4. a) 1. acrolein, 55 °C, 8 h, 2. aq. HCHO, NaOH, 55 °C, 4 h, 3. NaBH4, MeOH, overnight, 82%; b) 1. 
Na, NH3 (l), THF-EtOH, -45 °C, 2. BzCl, pyridine, overnight, 78 %; c) Dowex 50 (H+ cycle), 1,4-dioxane-water, 
reflux, 10 h, 75%; d) NaBH4, THF- H2O, 0 °C, 30 min, 88%; e) CH3CN, H2SO4-AcOH,  r.t., 1 h, 84%; f) KOH, 
EtOH-H2O, reflux, 9 h, 90%. 
 
Amine 212 was then used for the construction of target compounds (Scheme 5) by the same 
procedures as in the case of the syn-nucleosides. The double bond in each of the nucleosides 
213, 216, 217, 218 was utilized in two ways (Scheme 6). Saturated compounds 219, 220, 221, 
222 were obtained after hydrogenation over palladium hydroxide on charcoal. The 
compounds 223, 224, 225, and 226 with two cis-hydroxy groups were prepared by osmium 
tetroxide catalyzed cis-hydroxylation in an acetone-water mixture with N-methylmorpholine-
N-oxide (NMMO) as a recovering agent for osmium catalytic cycle. 
 Scheme 5. a) 1. 95, 1,4-dioxane, 100 °C, 3 h, 2. Dowex 50 (H+ cycle), 1,4-dioxane, 100 °C, 2.5 h, 55%; b) 1.  
4,6-dichlorpyrimidine-5-amine, Et3N, EtOH, 100 °C, 6 d, 2. HC(OEt)3, HCl, 2 d, 3. HCl, THF-H2O, 3 h, 63%; c) 
1. 4,6-dichlorpyrimidine-2,5-diamine, Et3N,EtOH, 100 °C, 6 d, 2. HC(OEt)3, HCl, 5 d 3. HCl, THF-H2O, 4 h, 
67%; d) NH3 (l), 75 °C, 2 d, 91%; e) cyclopropylamine, MeOH, overnight, 92% for 217, 80% for 218. 
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Scheme 6. a) H2, Pd(OH)2/C, MeOH-H2O; b) OsO4, NMMO, acetone-H2O. 
Compounds with a tricyclic skeleton were synthesized starting from the protected amide 211 
(Scheme 7). This compound was treated with m-chloroperbenzoic acid in dichloromethane 
and the epoxide 227 afforded the amine 228 by means of intramolecular oxirane ring opening 
under mild basic conditions (deprotection of the benzoyl groups by potassium carbonate). 
After that, acetyl protecting group was removed by potassium hydroxide. Nucleosides 229, 
230, 231 were prepared starting from amine 228, using the same procedures as described 
above.  
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Scheme 7. a) mCPBA, CH2Cl2, overnight, quant.; b) 1. K2CO3, MeOH, 2. KOH, EtOH-H2O, reflux, 9 h, 85%; c) 
1. 95, 1,4-dioxane, 100 °C, 3h, 2. Dowex 50 (H+ cycle), 1,4-dioxane, 100 °C, 2.5 h, 56%; d) 1. 4,6-
dichlorpyrimidine-5-amine, Et3N, EtOH, 100 °C, 6 d, 2. HC(OEt)3, HCl, 2 d, 2. HCl, THF-H2O, 3 h, 30%; e) 
cyclopropylamine, MeOH, overnight, 92%. 
 
The relative configuration (syn/anti) at the position 7 was confirmed by NOE experiment  
(compounds 174 and 214). For 174, a correlation was found between proton H-8´ (8.47 ppm) 
and protons H-5 (6.02 ppm) and H-6 (6.07 ppm) indicating syn-position of the nucleobase, 
while for 214, interaction between proton H-8´ (8.76 ppm) and proton H-3exo (1.85 ppm) 
indicating anti-position of the nucleobase was observed (Fig. 1).  
 Fig. 1. Important NOE interactions in compounds 174 and 214. 
 
Second part of the carbocyclic nucleoside project concerns the synthesis of the compounds 
with vicinal position of the nucleobase and hydroxymethyl group. Synthetic strategy was 
originally based on Michael addition of the nucleobase to the activated double bond. Addition 
of thymine to ester 232 in the presence of the base (DBU, K2CO3) gave moderate yields of 
isomers 233a and 233b (Scheme 8). Only isomers with trans configuration were observed in 
the reaction mixture and these were easily separated by column chromatography. The ratio of 
the exo-233a and endo-233b depended on the used base. In the case of DBU the ratio 
233a/233b was 3.5:1, whereas when potassium carbonate was used, the ratio was almost 
completely inversed - 1:2.5. However, this conjugate addition is not suitable for preparing 
purine nucleoside derivatives, yields of these additions were low and complicated reaction 
mixtures were obtained. 
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Scheme 8. a) Method I: thymine, DBU, DMF, 75 °C, 72 h, 35% for 233a, 10% for 233b; a) Method II: thymine, 
K2CO3, DMF, 75 °C, 72 h, 16% for 233a, 40% for 233b. 
 
Target thymine nucleosides were prepared by standard reaction procedures (Scheme 9). Ester 
group on unsaturated esters 233a and 233b was reduced with lithium aluminium hydride in 
tetrahydrofurane to afford hydroxymethyl group (236a and 236b). Saturated nucleosides 237a 
and 237b were prepared in two simple steps: the double bond was hydrogenated on palladium 
hydroxide and then the ester group was reduced to hydroxymethyl group with lithium 
aluminium hydride under the same conditions as for unsaturated compounds giving 237a and 
237b. Compounds 238a and 238b with two cis-hydroxy groups at the skeleton were prepared 
by osmium tetroxide catalyzed cis-hydroxylation followed by lithium aluminium hydride 
reduction.   
 
Scheme 9. a) H2, Pd(OH)2/C, MeOH-H2O, 86% for  234a, 84% for 234b; b) OsO4, NMMO, acetone-H2O, 98% 
for 235a, 91% for 235b; c) LiAlH4, THF, r.t., 54% for 236a, 69% for 236b 55% for 237a, 70% for 237b, 39% 
for 238a, 58% for 238b. 
 
When the Michael addition strategy failed, it was necessary to find a new route leading to the 
purine nucleosides. Curtius rearrangement was chosen for the introduction of the amino 
function (Scheme 10). The synthesis started with reaction of cyclopentadiene and fumaric 
acid monoethyl ester 239. Diels-Alder adducts were treated with iodine and sodium 
bicarbonate in the presence of potassium iodide in order to obtain to products - iodoacid 240a 
and iodoester 240b. This step allowed the separation of these crucial intermediates by simple 
acid/base extraction. Both individuals were utilized for preparation of the isomeric 
aminoalcohols 242a and 242b in four steps. Iodoacid 240a was firstly converted to Boc-
protected amine 241a by Curtius rearrangement. Double bond was restored with zinc in 
refluxing ethanol-water solution. Protected amino acid was immediately deprotected under 
acidic conditions and carboxylic acid was subsequently reduced with lithium aluminium 
hydride in THF to the aminoalcohol 242a. Synthesis of the aminoalcohol 242b was realized in 
a similar way, only the reaction sequence was different. Both amines were used crude for the 
next step and were fully characterized as acetyl derivatives 243a and 243b. The 
aminoalcohols 242a and 242b were used to build the target nucleoside analogues using 
standard and described synthetic procedures. Both saturated and cis-hydroxylated nucleoside 
analogues were prepared. 
  
Scheme 10. a) 1. cyclopentadiene, 1,4-dioxane, 60 °C, 1 h, 2. I2, KI, Na2CO3, H2O-CHCl3, r.t., overnight, 31% 
for 240a, 41% for 240b; b) 1. ClCOOEt, Et3N, acetone, 0 °C, 1 h, 2. NaN3, H2O-acetone, 0°C, 1 h, 3. toluene, t-
BuOH, reflux, 4 h, 51%; c) Zn, EtOH, reflux, 1 h, quant.; d) 1. Zn, EtOH, reflux, 2 h, 2. HCl, MeOH, 4 d 3. 
LiAlH4, THF, reflux, 12 h, 61%; e) 1. ClCOOEt, Et3N, acetone, 0 °C, 1 h, 2. NaN3, H2O-acetone, 0 °C, 1 h, 3. 
toluene, aq. HCl, reflux, 13 h; 4. LiAlH4, THF, reflux, 12 h, 67%; f)  Ac2O, pyridine, r.t., 80% for 243a, 92% for 
243b. 
 
Unfortunately, none of the prepared carbocyclic nucleosides showed any significant 
biological activity. 
 
Inhibitors of coxsackie B3 virus replication 
Two main groups of the novel coxsackie B3 virus inhibitors were synthesized. First group 
contained the derivatives with 6-chloropurines substituted in the position 9 with various 
bicylic systems. Second group of derivatives resulted from the systematic modification of the 
purine moiety of the selected lead structure 251b.  
The introduction of the nucleobase during the synthesis of 6-chloropurines (Fig. 2) was 
usually accomplished by Mitsunobu reaction. This reaction lead to 9-substituted-6-
chloropurines with exo orientation of the base to the bicyclic scaffold. Only 9-isomers were 
obtained in yields ranging from 14% to 78% after usual purification. Three derivatives were 
prepared by the construction of the nucleobase on appropriate amino precursor (Fig. 3).  
 
 Fig. 2. Derivatives prepared by Mitsunobu reaction. B = 6-chloropurine-9-yl. 
 
Fig. 3. Derivatives prepared by nucleobase-construction strategy. B = 6-chloropurine-9-yl. 
 
Compounds bearing various substituents on the norbornane scaffold (e.g. hydroxy, fluorine, 
ketogroup etc.) were also prepared in order to expand the library of the coxsackievirus 
inhibitors. Compounds were prepared by linear strategy involving Mitsunobu reaction as a 
key reaction. For the debenzoylations of protected 6-chloropurines intermediates we improved 
previously published method.4 Excess of methylmagnesium chloride in tetrahydrofurane at 
0 °C overnight and yields from 35-75% were obtained.  
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Fig. 4. Derivatives with variously substituted bicyclic scaffold. B = 6-chloropurine-9-yl. 
 
Second part of the coxsackie B3 virus inhibitors project was focused on the studying of the 
necessary nucleobase substitution. A small library of compounds was built up using well 
known synthetic procedures (nucleophilic aromatic substitution, cross-coupling reactions or 
conversion of  the function groups) to modify purine scaffold at the positions 2, 6, 8. Most of 
these compounds were prepared by 6-chloropurine derivatization of the lead structure  251b. 
This scaffold was chosen for this modifications due to its availability and chemical inactivity 
of the bicyclic scaffold. Structures of the prepared compounds are shown in the figures 5, 6 
and 7. 
 
 
 
Fig. 5. Purine modifications, position 6. 
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Fig. 6. Purine modifications, position 2. 
 
 
  
Fig. 7. Purine modifications, position 8. 
 
The results of the antiviral screening showed some interesting data. Most of the compounds 
exhibit a significant activity against coxsackie B3 virus with very low level of cytotoxicity to 
the Vero cells. The presence of the 6-chlorpurine as the nucleobase seems to be essential for 
the excellent antiviral activity. Most of the modifications in the purine part lead to lower 
antiviral activity, only compound bearing p-chlorophenyl substituent in position 6 embodied 
similar value of the EC50 (0.87±0.41 µM) to the parental compound. Several analogues 
inhibited CVB3 in the low micromolar range (0.66 µM - 2 µM). Some of the compounds 
showed comparable results or they are slightly better than previously prepared derivatives and 
are also comparable to the known inhibitor TTP-83075. Compounds 251b (EC50
 
=
 
0.81±0.20 
µM) and 259b (EC50 = 0.66±0.35 µM) are the best derivatives from this series. Studies to 
identify the molecular target of these compounds are in progress. Only three compounds from 
the group of bicyclic modified derivatives showed significant cytotoxicity to the Vero cell line 
(261b, 262b, 309), more cytotoxic compounds were found in the group of the purine modified 
derivatives (335, 337, 354, 355, 356, 358, 362).    
 
Conclusion 
In the first part of the thesis, three different types of the conformationally locked nucleoside 
analogues were prepared. In most cases, nucleobase was introduced to the bicyclic scaffold by 
built up strategy on an appropriate amino function. Three different synthetic pathways were 
used for preparation of suitable amines. For the 7-syn analogues, acid catalyzed 
decomposition of the intermediate triazolines connected with Wagner-Meervein 
rearrangement was used. The preparation of the isomeric anti-amine required totally different 
synthetic strategy where the key step was Ritter reaction in order to convert the hydroxy 
group to the acetamido group in excellent yield and which proceeded with retention of the 
configuration to achieve anti-configuration. Third used approach for preparation of the amino 
precursors was Curtius rearrangement of the suitable substituted bicyclic carboxylic acids. 
This step accompanied with function group transformations (ester reduction) furnished amine-
intermediates in good yield. Biological screening of the prepared compounds did not show 
any considerable activity. 
In the second part of the thesis, two large series of the coxsackie B3 virus inhibitors were 
designed and synthesized. This series uncovered a novel type of the coxsackie B3 virus 
inhibitors combining norbornane scaffold with 6-chlorpurine base. Two different types of the 
compounds were synthesized. Firstly, the bicyclic scaffold (OH, F, keto group, saturated, 
unsaturated scaffold etc.) was modified and as the nucleobase 6-chlorpurine was used. 
Nucleobases were generally introduced to the scaffold by Mitsunobu reaction in good yields. 
Second part was devoted to modifications at the purine part of the selected inhibitor (251b, 
easily available, very potent inhibitor), but these modifications did not improved the 
biological properties. Two most promising compounds 251b (EC50
 
=
 
0.81±0.20 µM) and 259b 
(EC50 = 0.66±0.35 µM) were selected for further investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
